Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
227 Clinical Trials near Fishers, IN
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerCarillon Device for Heart Failure with Mitral Regurgitation
Indianapolis, Indiana
This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Mitral Valve Pathology, Aortic Stenosis, Others
Must Be Taking:Heart Failure Medications
300 Participants Needed
Radiation Therapy for Early-Stage Breast Cancer
Indianapolis, Indiana
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, T4 Tumors, Others
Must Be Taking:Anti-HER2 Therapy
1636 Participants Needed
Penditure™ System for Left Atrial Appendage Closure
Carmel, Indiana
The purpose of this study is to collect post-market clinical evidence on performance and clinical outcomes of the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Cardiac Surgery History, Pericarditis, Thrombus, Others
150 Participants Needed
WATCHMAN Device for Atrial Fibrillation
Indianapoilis, Indiana
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Age < 18, Thrombus, Prior Occlusion, Others
Must Be Taking:Oral Anticoagulants
4000 Participants Needed
Genio Bilateral Stimulation for Obstructive Sleep Apnea
Carmel, Indiana
This trial tests a new device called the Genio® 2.1 System for people with moderate to severe sleep apnea. The device sends small electrical pulses to a nerve in the tongue, making it contract and keeping the airway open during sleep. The Genio® 2.1 System is part of a line of treatments involving electrical stimulation of the hypoglossal nerve to manage obstructive sleep apnea by maintaining airway patency.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22 - 75
Key Eligibility Criteria
Disqualifiers:Severe Insomnia, Hypertension, Alcohol Abuse, Others
Must Not Be Taking:Consciousness-altering, Anticoagulants
124 Participants Needed
LUX-Dx ICM Sensor Data Collection for Heart Failure
Indianapolis, Indiana
This trial aims to collect data from small devices placed under the skin that monitor heart activity. The focus is on patients with heart failure to gather information that can help create better diagnostic tools. The data collected will be compared with clinical tests and heart failure events to improve monitoring systems.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Other Active Devices, Heart Transplant, Amyloidosis, Others
525 Participants Needed
LimiFlex vs Fusion Surgery for Spinal Stenosis
Carmel, Indiana
The LimiFlex™ Clinical Trial is a prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of decompression and stabilization with the Empirical Spine LimiFlex™ Paraspinous Tension Band compared to decompression and transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) for the treatment of lumbar degenerative spondylolisthesis (Grade I per Meyerding classification) with spinal stenosis. Clinical trial sites will enroll solely LimiFlex subjects or solely TLIF/PLF subjects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:25 - 80
Key Eligibility Criteria
Disqualifiers:Discogenic Pain, Peripheral Neuropathy, Previous Surgery, Severe Osteoporosis, Others
Must Not Be Taking:Immunosuppressants, Steroids
299 Participants Needed
Cardiac MRI for Breast Cancer
Carmel, Indiana
This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Heart Disease, Hypertension, Diabetes, Others
Must Be Taking:Chemotherapy, Estrogen Antagonists
403 Participants Needed
Extended PREVENA Therapy for Post-Surgical Recovery
Fishers, Indiana
No Placebo Group
Trial Details
Trial Status:Withheld
Age:22+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Infection, Opioid Use, Others
Must Not Be Taking:Opioids, Steroids, Chemotherapy, Others
353 Participants Needed
Surgical Procedures for Reducing Ovarian Cancer Risk
Indianapolis, Indiana
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:35 - 50
Sex:Female
Key Eligibility Criteria
Disqualifiers:Prior Ovarian Cancer, Abnormal CA-125, Others
Must Not Be Taking:Cytotoxic Chemotherapy
1956 Participants Needed
Spesolimab for Hidradenitis Suppurativa
Indianapolis, Indiana
This trial tests spesolimab, a drug that may help adults with moderate to severe hidradenitis suppurativa (HS). It works by calming the immune system to reduce inflammation and heal the skin. The study aims to see if spesolimab is effective and safe for these patients.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
209 Participants Needed
Lebrikizumab for Eczema
Indianapolis, Indiana
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Key Eligibility Criteria
Disqualifiers:Not Listed
1188 Participants Needed
UCB0022 for Parkinson's Disease
Indianapolis, Indiana
This trial is testing UCB0022, a new medication, to see if it can help people with advanced Parkinson's Disease. It is added to their regular treatments to see if it reduces the time they spend with bad symptoms. The goal is to make their usual treatments work better.
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:35 - 85
Key Eligibility Criteria
Disqualifiers:Not Listed
207 Participants Needed
LEO 138559 for Eczema
Indianapolis, Indiana
This trial is testing a new medicine called LEO 138559 to treat adults with moderate to severe atopic dermatitis. The goal is to find out which amount works best to reduce symptoms like itching and redness.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
262 Participants Needed
Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)
Indianapolis, Indiana
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy.
The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy.
Study details include:
At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD).
The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up.
The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period.
The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Age:12+
Key Eligibility Criteria
Disqualifiers:Immunosuppression, Malignancies, Transplant, Infections, Others
Must Be Taking:Biologics, Oral JAKi
249 Participants Needed
Lebrikizumab for Eczema
Indianapolis, Indiana
This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:12+
Key Eligibility Criteria
Disqualifiers:Not Listed
120 Participants Needed
Izokibep for Hidradenitis Suppurativa
Indianapolis, Indiana
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
258 Participants Needed
Lebrikizumab for Eczema
Indianapolis, Indiana
This trial is testing lebrikizumab, a medication that reduces inflammation, in adolescents and adults with severe eczema and skin of color. The goal is to see if it is safe and effective for these patients.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:12+
Key Eligibility Criteria
Disqualifiers:Not Listed
80 Participants Needed
Ruxolitinib Cream for Atopic Dermatitis/Eczema
Indianapolis, Indiana
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.
No Placebo Group
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
100 Participants Needed
Barzolvolimab for Chronic Hives
Indianapolis, Indiana
This trial is testing a new medication called barzolvolimab to help people with Chronic Spontaneous Urticaria, a condition that causes persistent hives and itching. The medication works by calming the immune system to reduce these symptoms.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
208 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
SEA-CD40 Combination Therapy for Non-Small Cell Lung Cancer
Indianapolis, Indiana
This trial is testing a new drug called SEA-CD40 to see if it can help treat certain types of cancer when used with other medications. It targets patients with hard-to-treat melanoma and advanced lung cancer. The drug works by boosting the immune system and working with other drugs to attack cancer cells. This new treatment option has the potential to generate anticancer immunity through various mechanisms.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
77 Participants Needed
Bimekizumab for Plaque Psoriasis
Indianapolis, Indiana
This trial is testing how the body processes bimekizumab, a medication given as an injection, in teenagers with serious psoriasis. The goal is to see if it can help reduce their skin problems by blocking inflammation-causing proteins. Bimekizumab has shown high effectiveness in treating moderate to severe psoriasis.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:12 - 17
Key Eligibility Criteria
Disqualifiers:Not Listed
41 Participants Needed
KB-0742 for Cancer
Indianapolis, Indiana
Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).
Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:12+
Key Eligibility Criteria
Disqualifiers:Not Listed
280 Participants Needed
Navitoclax + Ruxolitinib for Myelofibrosis
Indianapolis, Indiana
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
191 Participants Needed
RGX-202-01 Combination Therapy for Colorectal Cancer
Indianapolis, Indiana
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal adenocarcinoma. The single agent ompenaclid dose escalation stage and the ompenaclid in combination with FOLFIRI and bevacizumab dose escalation stage of the study has been completed; the expansion stage of ompenaclid in combination with FOLFIRI and bevacizumab is ongoing. In April-24 a protocol amendment added a new dose escalation and expansion stage which will evaluate ompenaclid in combination with FOLFOX and bevacizumab in patients with metastatic CRC. It is anticipated that a total of 30 patients will be enrolled in this new dose escalation and expansion stage of the study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
108 Participants Needed
Communication Intervention for Cancer Care
Carmel, Indiana
The purpose of this study is to help test an idea designed to foster more supportive talk between providers (doctors or nurse practitioners), patients, and caregivers during an outpatient oncology appointment. A caregiver is the person the patient identifies is primarily involved in their healthcare. This study is collecting your reaction to this idea in order to understand needed changes before we introduce the idea to a larger group of patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
60 Participants Needed
X-ray for Bone Density
Fishers, Indiana
The purpose of this research is to collect medical imaging data to allow for the comparison of bone mineral density measurements from two low-dose x-ray exams. The main question it aims to answer is:
What is the precision measurement between the BMD assessments from 2 x-ray exams?
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:20+
Key Eligibility Criteria
Disqualifiers:Not Listed
30 Participants Needed
Nanofiber Scaffold for Rotator Cuff Tears
Fishers, Indiana
Randomized controlled trial of patients over the age of 55 treated with and without a nanofiber scaffold during rotator cuff repair.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:55+
Key Eligibility Criteria
Disqualifiers:Not Listed
91 Participants Needed
Retatrutide for Type 2 Diabetes and Obesity
Indianapolis, Indiana
This trial is testing retatrutide, a medication for people with type 2 diabetes who are overweight or obese, including some with sleep apnea. The medication aims to help control blood sugar levels and may also aid in weight loss.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Thyroid Carcinoma, Pancreatitis, Others
Must Not Be Taking:Weight Loss Drugs, Stimulants
1000 Participants Needed
Retatrutide for Obesity
Indianapolis, Indiana
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Thyroid Carcinoma, Pancreatitis, Others
Must Not Be Taking:Weight Loss Drugs, Stimulants, Hypnotics, Others
2300 Participants Needed
Know someone looking for new options?
Spread the word